Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America.

Content Provider	Europe PMC
Author	Bove, Virginia Riva, Eloísa Vásquez, Jule Peña, Camila Seehaus, Cristian Samanez, César Bustos, Justina Hernández, Marcos Fernández, Julio Ríos, Oliday Rodríguez, Yusaima Figueredo, Irving Fantl, Dorotea Malpica, Luis
Copyright Year	2022
Abstract	PURPOSEInfections are a significant cause of morbidity and mortality in patients with multiple myeloma (MM). In Latin America, data on infectious complications in this patient population are lacking.METHODSWe conducted a prospective cohort study of patients with newly diagnosed MM (NDMM) in seven Latin American countries between June 2019 and May 2020. Patients with active disease, on active therapy, and with a follow-up of 6 months from the time of diagnosis were included. Our primary end point was the number of infectious events that required hospitalization for ≥ 24 hours.RESULTSOf 248 patients with NDMM, 89 (35.9%) had infectious complications (113 infectious events), the majority (67.3%) within the first 3 months from diagnosis. The most common sites of infection were respiratory (38%) and urinary tract (31%). The microbial agent was identified in 57.5% of patients with gram-negative bacteria (73.5%) as the most common pathogen. Viral infections were infrequent, and no patients with fungal infection were reported. In the multivariable analysis, diabetes mellitus (odds ratio [OR], 2.71; 95% CI, 1.23 to 6.00; P = .014), creatinine ≥ 2 mg/dL (OR, 4.87; 95% CI, 2.29 to 10.35; P < .001), no use of trimethoprim-sulfamethoxazole prophylaxis (OR, 6.66; 95% CI, 3.43 to 12.92; P < .001), and treatment with immunomodulatory drugs (OR, 3.02; 95% CI, 1.24 to 6.29; P = .003) were independent factors associated with bacterial infections. At 6 months, 21 patients (8.5%) had died, 47.6% related to infectious complications.CONCLUSIONBacterial infections are a substantial cause of hospital admissions and early death in patients with NDMM. Antibiotic prophylaxis should be considered to reduce infectious complications in patients with MM.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9812460&blobtype=pdf
Journal	JCO Global Oncology [JCO Glob Oncol]
Volume Number	8
PubMed Central reference number	PMC9812460
PubMed reference number	35867949
e-ISSN	26878941
DOI	10.1200/go.22.00068
Language	English
Publisher	Wolters Kluwer Health
Publisher Date	2022-07-01
Access Restriction	Open
Rights License	Creative Commons Attribution Non-Commercial No Derivatives 4.0 License http://creativecommons.org/licenses/by-nc-nd/4.0/ © 2022 by American Society of Clinical Oncology
Content Type	Text
Resource Type	Article
Subject	Medicine Oncology Cancer Research